Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.45 |
| ▸ | EPHA2 | P29317 | 2/20 | 0.42 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.41 |
| ▸ | FEN1 | P39748 | 3/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.39 |
| ▸ | CCNK | O75909 | 1/20 | 0.38 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 2/20 | 0.37 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20711699 | 1.00 | IDO1 (0.46) | IDO1TDO2SCN9AEPHA2ALOX5AP | |
| SCHEMBL20699309 | 0.94 | SCN9A (0.41) | IDO1TDO2SCN9AEPHA2ALOX5AP | |
| SCHEMBL30161443 | 0.94 | SCN9A (0.41) | IDO1TDO2SCN9AEPHA2ALOX5AP | |
| SCHEMBL20699406 | 0.88 | RXRA (0.39) | IDO1TDO2 | |
| SCHEMBL22198743 | 0.88 | IDO1 (0.48) | IDO1TDO2SCN9AALOX5APFEN1 | |
| SCHEMBL29607199 | 0.87 | GPR119 (0.43) | SCN9AALOX5APFEN1GPR119USP30 | |
| SCHEMBL20711771 | 0.87 | GPR119 (0.43) | SCN9AALOX5APFEN1GPR119USP30 | |
| SCHEMBL28380561 | 0.86 | SCN9A (0.43) | IDO1TDO2SCN9AEPHA2ALOX5AP | |
| SCHEMBL29606683 | 0.86 | SCN9A (0.43) | IDO1TDO2SCN9AEPHA2ALOX5AP | |
| SCHEMBL20711762 | 0.86 | PDE4B (0.43) | IDO1TDO2USP30CCNKCDK12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111032646-B | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | 施万生物制药研发IP有限责任公司 | 2023-01-03 | — | — | CN | disclosed |
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119369-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | IDO1 566/4885TDO2 1694/4885SCN9A 3164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.